insiderwall
Menu
SuperinvestorInsider
Summit Therapeutics Inc. SMMT

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicinal therapies designed to be patient, physician, caregiver, and societally friendly. Its lead candidate, ivonescimab, is a first-in-class bispecific antibody that simultaneously targe

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees265
TickerSMMT

Statistics

Market Cap$11.07B
Revenue (TTM)
Net Income-$1.08B
Net Margin
EPS$-1.44
P/E25.02
P/S
P/B18.58
EV/EBITDA-7.83
ROE-271.0%
Dividend Yield
Price$14.26

Data: Twelve Data · Revenue = mcap / P/S